etokimab
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02920021)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-33BINDING AGENT
Interleukin-33 binding agent
- Interleukin-33INHIBITOR
IL33 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297580 ↗
Also known as
- anb020
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03614923 | Phase 2 | Oct 31, 2018 | AnaptysBio, Inc. |
| NCT03533751 | Phase 2 | May 23, 2018 | AnaptysBio, Inc. |
| NCT03469934 | Phase 2 | Nov 14, 2017 | AnaptysBio, Inc. |
| NCT02920021 | Phase 2 | Dec 1, 2016 | AnaptysBio, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnaptysBio, Inc. | For profit | 4 | 4 | 1 | 2016 |
1 organizations
Page 1 / 1